Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CHIKV VLP vaccine · 1 trial · 1 indication
Laboratory-confirmed acute CHIKV disease is defined by the presence of fever, one or more of arthralgia, myalgia or rash, and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) confirmation of CHIKV ribonucleic acid.
| Arm | Type | Description |
|---|---|---|
| Arm 1: Cohort 1 Active Group | ACTIVE_COMPARATOR | CHIKV VLP/adjuvant |
| Arm 2: Cohort 1 Placebo Group | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| CHIKV VLP vaccine | BIOLOGICAL | CHIKV VLP vaccine is comprised of 40 µg CHIKV VLP adsorbed on aluminum hydroxide (corresponding to approximately 300 µg of aluminum and stabilized with formulation buffer). CHIKV VLP vaccine is supplied as a single dose of 0.8 mL in a single use pre-filled syringe administered via IM injection in the deltoid muscle. |
| Placebo | BIOLOGICAL | Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a single use pre-filled syringe administered via IM injection in the deltoid muscle. |
Inclusion Criteria: 1. Able and willing to provide informed consent (and assent, as applicable) voluntarily signed by participant (and guardian, as applicable). Must verbalize understanding of the reason for and the procedures needed for the study and be willing to stay in the study for its entire ...
CHIKV VLP vaccine is an investigational vaccine being studied for the prevention of chikungunya disease in adolescents and adults. It is currently in Phase 3 clinical development for the Chikungunya Virus indication, which falls under the Infectious Disease therapeutic area.
CHIKV VLP vaccine is being developed by United Therapeutics Corporation, a company traded on the NASDAQ under the ticker symbol UTHR. The vaccine is currently in Phase 3 clinical development for the prevention of chikungunya disease.
CHIKV VLP vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The ongoing Phase 3 trial is designed to evaluate the efficacy, safety, and immunogenicity of the vaccine for the prevention of chikungunya disease.
CHIKV VLP vaccine is being evaluated in a single Phase 3 clinical trial registered as NCT07467707. This randomized, double-blind, placebo-controlled study is assessing the efficacy, safety, and immunogenicity of the vaccine for the prevention of chikungunya disease in adolescents and adults, with an enrollment target of 6,144 participants.
CHIKV VLP vaccine is a vaccine candidate specifically designed to prevent chikungunya disease caused by the Chikungunya Virus. It is a virus-like particle (VLP) vaccine, which is a type of vaccine that mimics the structure of the virus to elicit an immune response without causing the disease.